Table 3.

Change-from-baseline QTcF (ΔQTcF, ms) across study treatments and time points (C-QTcF population).

Timepoint	Treatment	N	Mean	90 % Confidence Interval
DAY 1: pre 1 pm dose	LFX 2.16	202	1.9	0.8	3.1
	LFX 2.88	194	2.9	1.7	4.2
	Placebo	151	−0.7	−2.0	0.6
DAY 1: 4 pm	LFX 2.16	200	4.7	3.4	6.0
	LFX 2.88	187	6.2	4.6	7.9
	Placebo	139	0.8	−0.8	2.3
DAY 1: 5 pm	LFX 2.16	191	3.9	2.6	5.2
	LFX 2.88	182	3.9	2.2	5.5
	Placebo	135	0.0	−1.4	1.4
DAY 2: pre 8 am dose	LFX 2.16	177	4.2	2.7	5.6
	LFX 2.88	172	7.4	5.8	9.1
	Placebo	118	1.4	−0.3	3.0
DAY 4: pre 8 am dose	LFX 2.16	114	0.0	−2.2	2.3
	LFX 2.88	119	1.5	−0.9	4.0
	Placebo	74	0.4	−2.9	3.8
DAY 7: pre 8 am dose	LFX 2.16	91	−6.0	−8.5	−3.6
	LFX 2.88	99	−4.0	−6.8	−1.3
	Placebo	58	−2.4	−6.4	1.7
DAY 7: pre 1 pm dose	LFX 2.16	54	−4.1	−7.2	−1.1
	LFX 2.88	68	−7.8	−11.1	−4.6
	Placebo	37	−4.7	−8.5	−1.0
DAY 7: 4 pm	LFX 2.16	54	−4.2	−7.8	−0.6
	LFX 2.88	63	−7.6	−10.6	−4.5
	Plascebo	37	−6.6	−10.7	−2.4
DAY 7: 5 pm	LFX 2.16	54	−5.3	−8.6	−2.0
	LFX 2.88	65	−8.1	−11.6	−4.6
	Placebo	37	−6.0	−10.3	−1.7

LFX, lofexidine; QTcF, QT interval corrected, Fridericia formula.